Cybin (CYBN) - יתרות מזומנים בחישוב למניה

Strict FDA oversight and the patent protection of Cybin Inc. (CYBN) contrast with the rigorous control of biosample transportation. The cash-per-share valuation helps balance these factors, with the parameter stabilizing at 1.68. The company's current strategy relies on securing a major pharmaceutical partner to co-fund the subsequent stages of clinical trials.
פילוחים אנליטיים של חברת Cybin Inc.

Cash per share dynamics reflect the ability of Cybin Inc. (CYBN) to fund psychedelic development in the absence of revenue and amid a dependence on external capital injections. This metric is calculated by dividing total liquid assets by the number of shares outstanding, measuring the actual cash reserve per share, which allows investors to assess the capital runway before the next issuance round.